Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 12 May 2026
An act of Congress forced the administration to reverse course
Read Full NewsNew York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.
The drug was previously approved for stage 2 T1D.
Findings suggest young females should be assessed and, if at risk, monitored.
Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.
Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.
The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.
Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.
1.
Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target
2.
Is global cancer care losing its human touch?
3.
New study links air pollution with higher rates of head and neck cancer
4.
Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?
5.
Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs
1.
Contemporary Trends in Oncology and Patient Outcomes
2.
Survival Rates in Cancer: Focus on Acute Myeloid Leukemia and Other Malignancies
3.
Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025
4.
Emerging Frameworks in Oncology in Clinical Decision-Making
5.
The Basics of M.C.V Normal Range for Better Health Management
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
2.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
3.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge